Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of polypeptide, polypeptide fragments and derivatives thereof in the prevention and treatment of fibrotic diseases

A technology of fibrotic diseases and polypeptide fragments, applied in bone diseases, respiratory diseases, urinary system diseases, etc., can solve the problems of reducing adverse reactions, achieve inhibition of inflammation and fibrosis, reduce inflammatory cell infiltration, prevent and The effect of treating fibrotic diseases

Active Publication Date: 2019-02-26
CHENGDU HUITAI BIOMEDICINE CO LTD
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Marketed fatty acid modified peptide drugs such as liraglutide (Liraglutide, Novo Nordisk) for the treatment of type 2 diabetes, liraglutide replaces the 34th lysine (Lys) of human GLP-1 with arginine acid (Arg), and introduced a 16-carbon palmitic acid side chain mediated by glutamic acid (Glu) on the 26-position Lys, which significantly reduced the adverse reactions of GLP-1, but completely retained its biological activity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of polypeptide, polypeptide fragments and derivatives thereof in the prevention and treatment of fibrotic diseases
  • Application of polypeptide, polypeptide fragments and derivatives thereof in the prevention and treatment of fibrotic diseases
  • Application of polypeptide, polypeptide fragments and derivatives thereof in the prevention and treatment of fibrotic diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0074] Example 1 Polypeptide and Rat Pulmonary Fibrosis Model

[0075] 1. Main experimental materials and animals

[0076] Bleomycin was produced by Hisun-Pfizer Pharmaceuticals Co., Ltd. (batch numbers 16037911, 16033811); Shutai 50 anesthetic was produced by Vic Co., Ltd. of France.

[0077] Peptides, polypeptide fragments and their derivatives SEQ ID NO: 1 (N1 for short), SEQ ID NO: 2 (N2 for short), SEQ ID NO: 3 (N3 for short), SEQ ID NO: 4 (N4 for short), SEQ ID NO : 5 (abbreviated as N5), SEQ ID NO: 6 (abbreviated as N6), SEQ ID NO: 7 (abbreviated as N7), and SEQ ID NO: 8 (abbreviated as N8) were synthesized by Chengdu Capgemini Biomedical Technology Development Co., Ltd., and its sequence is as follows Shown as SEQ ID NO: 1 to SEQ ID NO: 8 in the list.

[0078] SPF grade SD rats were purchased from Chengdu Dashuo Experimental Animal Co., Ltd., male, weighing 200-250 g.

[0079] 2. Rat model of pulmonary fibrosis

[0080] Weigh before administration, intramuscularly ...

Embodiment 2

[0082] Example 2 Detection of Active TGF-β Content in Rat Lung Tissue by ELISA

[0083] Take the lung tissue of the rats in the model group of Example 1, the control group and the N1 treatment group, use RIPA lysate (100 mg of lung tissue corresponds to 1 mL of lysate) for tissue homogenization, centrifuge to get the supernatant, and use the BCA method to determine the protein concentration. Take an equal amount of protein samples, and use enzyme-linked immunosorbent assay (Promega, product number G7591) to detect the content of active TGF-β (results in figure 1 ), biostatistical analysis was performed using one-way ANOVA.

[0084] Compared with the control group, the content of active TGF-β in the lung tissue of rats in the model group increased significantly (**: p p <0.05), indicating that N1 can significantly inhibit the activation of TGF-β induced by bleomycin.

Embodiment 3

[0085] Embodiment 3 qPCR method detects in rat lung tissue ctgf , Collagen Ⅰ and Collagen Ⅲ content

[0086] The lung tissues of the rats in the model group, control group and N1 treatment group in Example 1 were taken, and RNA in the lung tissues was extracted by using the TRIZOL (Invitrogen) method. After reverse transcription to obtain cDNA, the fluorescent quantitative PCR (qPCR) kit (Applied Biosystems, Cat. No. 4319413E) Detection of TGF-β pathway downstream gene connective tissue growth factor ctgf (forward primer: 5'-TGGCCCTGACCCAACTATGA-3', reverse primer: 5'-CTTAGAACAGGCGTCCCACTCT-3'), collagen I (forward primer: 5'-TGCCGATGTCGCTATCCA-3', reverse primer: 5'-TCTTGCAGTGATAGGTGATGTTCTG -3') and collagen III (forward primer: 5'-GGAAAAGATGGATCAAGTGGACAT-3', reverse primer: 5'-GAGCCCTCAGATCCTCTTTCAC-3'), 18s RNA was used as an internal reference (results in figure 2 ), biostatistical analysis was performed using one-way ANOVA.

[0087] Compared with the control group...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of a medicine and relates to the field of prevention and treatment of fibrotic diseases, and discloses polypeptide, polypeptide fragments and derivatives thereof, and an application of polypeptide, polypeptide fragments and derivatives in preparing medicines for preventing and treating fibrotic diseases. The present invention relates to a product afteramino acid deletion, addition, and replacement of the polypeptide, and relates to the application of a chemically modified product, a composition of the polypeptide, the polypeptide fragment and the derivative thereof, pharmaceutically available carriers and dosage forms, and drugs for prevention and treatment of fibrotic diseases. The polypeptide, the polypeptide fragment and the derivative thereof can effectively inhibit the development of tissue and organ inflammation and fibrosis, and have an ideal new drug development value.

Description

technical field [0001] The invention belongs to the technical field of medicine and relates to the field of prevention and treatment of fibrotic diseases, in particular to the application of polypeptides, polypeptide fragments and derivatives thereof in the preparation of drugs for preventing and / or treating fibrotic diseases. Background technique [0002] Fibrosis is the excessive deposition and remodeling disorder of fibrous connective tissue caused by the increase of extracellular matrix such as collagen and fibronectin in and around the injury site or inflammatory lesion, which will cause permanent scars, organ dysfunction and even death. Fibrosis is closely related to the occurrence of many diseases. This common clinical pathological change is the final pathological outcome of common chronic inflammatory diseases and the main pathological symptom of chronic autoimmune diseases. It can also affect tumor invasion and metastasis and chronic transplantation. Rejection. Fib...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/08A61K38/10A61P29/00A61P19/02A61P11/00A61P11/06A61P1/16A61P13/12A61P19/08A61P9/00
CPCA61K38/00C07K7/08
Inventor 韦德丁怡李小梅肖玲陈晓红俞雯
Owner CHENGDU HUITAI BIOMEDICINE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com